Journal
CELL REPORTS
Volume 16, Issue 3, Pages 631-643Publisher
CELL PRESS
DOI: 10.1016/j.celrep.2016.06.020
Keywords
-
Categories
Funding
- WKO grant
- Synergy ERC grant
- National Roadmap grant for Large-Scale Research Facilities of the Netherlands Organization for Scientific Research
- Dutch Cancer Society
Ask authors/readers for more resources
Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor, and no effective treatment is available to date. Mouse models of SCLC based on the inactivation of Rb1 and Trp53 show frequent amplifications of the Nfib and Mycl genes. Here, we report that, although overexpression of either transcription factor accelerates tumor growth, NFIB specifically promotes metastatic spread. High NFIB levels are associated with expansive growth of a poorly differentiated and almost exclusively E-cadherin (CDH1)negative invasive tumor cell population. Consistent with the mouse data, we find that NFIB is over-expressed in almost all tested human metastatic high-grade neuroendocrine lung tumors, warranting further assessment of NFIB as a tumor progression marker in a clinical setting.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available